<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053308</url>
  </required_header>
  <id_info>
    <org_study_id>2012-144-1183</org_study_id>
    <nct_id>NCT05053308</nct_id>
  </id_info>
  <brief_title>Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement</brief_title>
  <official_title>Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement Versus Intravenous PCA for Breakthrough Cancer Pain: A Prospective, Randomized, Open Label, Non Inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proportional dose of sublingual fentanyl tablet (Narco®) based on daily opioid requirement&#xD;
      versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label,&#xD;
      noninferiority trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the previous around-the-clock analgesic demand compared to IV PCA in cancer pain&#xD;
      patients to prepare the basis for the administration of fentanyl sublingual tablets with an&#xD;
      initial dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 11-point scale NRS pain score</measure>
    <time_frame>30 minutes after administration</time_frame>
    <description>Change in pain score compared to baseline Score '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 11-point scale NRS pain score</measure>
    <time_frame>15, 45, 60 minutes after administration</time_frame>
    <description>Change in pain score compared to baseline Score '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sum of pain intensity difference(SPID)</measure>
    <time_frame>60 minutes after administration</time_frame>
    <description>sum of pain intensity change compared to baseline difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of additional doses</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>number of additional doses fentanyl bolus or subligual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Pain interference using BPI-SF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>The severity of insomnia using ISI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>The severity of depression using Beck Depression Inventory(BDI) 1-10: These ups and downs are considered normal 11-16: Mild mood disturbance 17-20: Borderline clinical depression 21-30: Moderate depression 31-40: Severe depression over 40: Extreme depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction scale</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Satisfaction check using 5 Likert-scale&#xD;
(1) Very dissatisfied; (2) Not satisfied; (3) Neutral; (4) Satisfied; (5) Very satidfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cancer Pain</condition>
  <condition>Breakthrough Pain</condition>
  <arm_group>
    <arm_group_label>IV PCA (proportional dosage)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Breakthrough pain control by bolus based IV patient-controlled anagesia Fentanyl bolus = MME * 15%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SL-FTN (equivalent dose for PCA bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breakthrough pain control by sublingual fentanyl Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Infusion</intervention_name>
    <description>IV PCA(fentanyl) Fentanyl bolus = MME * 15%</description>
    <arm_group_label>IV PCA (proportional dosage)</arm_group_label>
    <other_name>PCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Tablet</intervention_name>
    <description>subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.</description>
    <arm_group_label>SL-FTN (equivalent dose for PCA bolus)</arm_group_label>
    <other_name>sublingual</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19-80&#xD;
&#xD;
          -  Cancer pain&#xD;
&#xD;
          -  Admission for the control of cancer pain or consultation for the treatment of cancer&#xD;
             pain&#xD;
&#xD;
          -  Stable vital sign&#xD;
&#xD;
          -  ECOG status ≤ 3 for more than 1 or 2 months&#xD;
&#xD;
          -  Opioid-tolerant state&#xD;
&#xD;
          -  No history of using sublingual fentanyl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Noncancer pain&#xD;
&#xD;
          -  Opioid naive&#xD;
&#xD;
          -  baseline NRS pain score&gt; 4&#xD;
&#xD;
          -  Current using sublingual fentanyl&#xD;
&#xD;
          -  Difficult to assess cancer pain&#xD;
&#xD;
          -  no evidence of disease(cancer)&#xD;
&#xD;
          -  Planned surgical resection of cancer&#xD;
&#xD;
          -  Allergy to fentanyl&#xD;
&#xD;
          -  Severe renal and/or liver function&#xD;
&#xD;
          -  Severe respiratory depression or uncontrolled COPD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jee Youn Moon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jee Youn Moon, MD, PhD</last_name>
    <phone>82-2-2072-2467</phone>
    <email>jymoon0901@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongjae Yoo, MD, PhD</last_name>
    <phone>82-2-2072-2952</phone>
    <email>rkdarkef@gmail.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University</investigator_affiliation>
    <investigator_full_name>Jeeyoun Moon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

